Fennec Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript
Presentation is from Fennec Pharmaceuticals, and we have Adrian Haigh, this year.
Thanks. Morning, everybody. Just the Safe Harbor statement, just a bit of background on me. First of all, I've been a Board Director Fennec for almost 10 years. I gave up the day job where I was head of PTC international, back in January, I spent six months retired but joined full time as Chief Operating Officer in August of this year.
So PEDMARK is a commercial stage pharmaceutical company. We've got one asset, which is PEDMARK, which is a specially formulated solution of sodium thiosulfate indicated to prevent cyst platinum induced hearing loss in pediatric patients. We have Orange Book Patent exclusivity in the US until 2039 on the formulations. We have seven years off-drug exclusivity in the US, and we have a PUMA, a pediatric use marketing authorization in Europe.
We launched commercially in the US in October of last year and we expect to launch in Europe in June of next year. The reason for that is we had
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
